Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support ...

Regeneron Pharmaceuticals and Sanofi are conducting a Phase 3 clinical study titled A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Invest ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Sanofi, Regeneron eye $11B in Dupixent sales with ... The move will cause "no change" to their ongoing partnership, the companies said. Sanofi will retain about 400,000 shares in Regeneron stock ...

Sanofi and Regeneron rejiggered their longstanding antibody ... The move will cause "no change" to their ongoing partnership, the companies said. Sanofi will retain around 400,000 shares in ...

With support from Sanofi and Regeneron, Viz.ai will investigate the use of the Viz COPD module, a care acceleration solution that will leverage electronic health record (EHR) data and artificial ...

NEW YORK, Nov 10 (Reuters) - Regeneron Pharmaceuticals Inc and French drugmaker Sanofi-aventis said on Tuesday they have expanded their partnership to develop a number of Regeneron's experimental ...

Sanofi recognizes all revenue from antibodies in the partnership. The drug accounted for €10.7 billion (about $11.6 billion) in sales in 2023, up nearly 30% from the prior year, according to the ...

Tucked away in the middle of its second-quarter results today, Regeneron announced that it and long-term Big Pharma partner Sanofi will end their antibody research partnership before 2018.

Sanofi’s R&D site in Vitry-Sur-Seine, near Paris. Sanofi and Regeneron said that drug candidate Itepekimab didn’t hit the main objective of a second trial.